



# **iJRASET**

International Journal For Research in  
Applied Science and Engineering Technology



---

# **INTERNATIONAL JOURNAL FOR RESEARCH**

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

---

**Volume:** 12    **Issue:** IV    **Month of publication:** April 2024

**DOI:** <https://doi.org/10.22214/ijraset.2024.59875>

**[www.ijraset.com](http://www.ijraset.com)**

**Call:** ☎ 08813907089

**E-mail ID:** [ijraset@gmail.com](mailto:ijraset@gmail.com)

# Comparative Effectiveness of *Varunadi Ghan Vati* and *Kanchnar Guggulu* in Management of Subclinical Hypothyroidism- Study Protocol for a Randomized Controlled Trial

Dr. Himanshi Jangra<sup>1</sup>, Dr. Neha Lamba<sup>2</sup>, Dr. Neelam Kumari<sup>3</sup>, Dr. Piyush Chaudhay<sup>4</sup>

<sup>1</sup>P.G. Scholar, P.G. Department of Kayachikitsa, Institute For Ayurved Studies & Research, Faculty of Ayurved, SKAU, Kurukshetra, Haryana

<sup>2</sup>Associate professor, P.G. Department of Kayachikitsa, Institute For Ayurved Studies & Research, Faculty of Ayurved, SKAU, Kurukshetra, Haryana

<sup>3</sup>Professor & Chairperson, P.G. Department of Kayachikitsa, Institute For Ayurved Studies & Research, Faculty of Ayurved, SKAU, Kurukshetra, Haryana

<sup>4</sup>Assistant Professor, MSM Institute of Ayurveda Bhagat Phool Singh Mahila Vishwavidyalaya Khanpur Kalan, Sonapat, Haryana

**Abstract: Background:** Hypothyroidism is an emerging disease nowadays. India has a high prevalence of Hypothyroidism, which is about 10%. Hormone replacement therapy is advised in the treatment of hypothyroidism. However, in subclinical hypothyroidism, no treatment is advised. Ayurveda describes a number of treatment modalities for the treatment of disease on the basis of their dosha-dushya. The aim of this study is to evaluate the effectiveness of *Varunadi Ghan Vati* in comparison with *Kanchnar Guggulu* in the management of subclinical hypothyroidism.

**Methods and Design:** This study will be a prospective, single-centered, randomized controlled trial. A total of 60 patients of age between 19 and 60 years, diagnosed with subclinical hypothyroidism, and presented with cardinal features of the disease will be randomized into two groups. In Group A, patients will be given *Varunadi Ghan Vati* and in Group B patients will be given *Kanchnar Guggulu*. Pathya-Apathya regarding the disease will be guided to both groups. Both groups will receive treatment for 45 days. Outcomes will be evaluated on the 15<sup>th</sup>, 30<sup>th</sup> and 45<sup>th</sup> days (during treatment) and 75<sup>th</sup> day (post-treatment). The primary outcome will be evaluated on the basis of cardinal symptoms of subclinical hypothyroidism. Improvement in laboratory investigations will be evaluated for secondary outcomes.

**Conclusion:** This trial is the first to compare the effectiveness of *Varunadi Ghan Vati* with *Kanchnar Guggulu* in the management of subclinical hypothyroidism. *Varunadi Ghan Vati* is expected to improve the symptoms of subclinical hypothyroidism, thus proving to be effective in the management of patients with subclinical hypothyroidism.

**Trial registration:** CTRI/2023/07/055295.

**Keywords:** subclinical hypothyroidism, randomized trial, *Varunadi Ghan Vati*, *Kanchnar Guggulu*, controlled trial.

## I. BACKGROUND

In the modern era, the sedentary lifestyle, physical inactivity, and unhealthy food habits give rise to many metabolic disorders like obesity, type 2 diabetes, hypertension, hypothyroidism etc. Hypothyroidism is a disorder occurring due to hyperfunctioning of the thyroid gland. The subclinical form of hypothyroidism is the phase of compensation when TSH levels are raised than normal while T3 and T4 are within normal range in the blood.<sup>[1]</sup> Subclinical hypothyroidism is either asymptomatic or present with symptoms like puffiness of face and eyelids, bilateral periorbital oedema, dry skin and coarse skin, breathlessness, cold intolerance, hoarseness of voice, constipation, weight gain, fatigue, body ache, hair fall along with impaired menstrual cycle.<sup>[2]</sup> The prevalence of hypothyroidism is about 4-5%.<sup>[3]</sup> and subclinical hypothyroidism is about 4-15%.<sup>[4]</sup> India has a high prevalence of hypothyroidism, which is about 10%. It is much more common in females than in males.<sup>[5]</sup> Though there is no direct description of this disease in Ayurvedic text, there is a description in *Ashtanga Hridayam* that if the *Vaidya* does not know the disease name, he can treat the disease according to its *prakriti*, *adhithan*, *bheda* and *hetu*.<sup>[6]</sup> According to Ayurveda, the metabolic processes of the body are under the control of *Jatharagni*, *Bhutagni*, *Dhatvagni* and *Doshas*.

The symptoms of subclinical hypothyroidism are developed due to alteration of metabolic activity; which according to Ayurveda, can be hypothesized- vitiation of mainly *Kapha Dosha*, *Ras Dhatvagni* and *vitiating Vata* due to *Margavarodha* by *Kapha*.<sup>[7]</sup>




Figure 1 : samprapti chakra

Vitiation of *Rasa Dhatu* and *Kapha doshas* along with vitiation of *Vata dosha* can produce symptoms of subclinical hypothyroidism. The clinical picture of the disease shows the dominance of *Kapha Dosha*. The majority of the *Nanatmaja Roga* of *Kapha Dosha*<sup>[8]</sup> such as *Alasya* (laziness/lethargy), *nindra-adhikya* (hypersomnia), *Tandra* (drowsiness), *apakti* (indigestion), *galganda* (goitre), *gurugatrata* (body heaviness), *balasak* (asthenia), *shwetabhasta* (pallor), *sheetagnita* (impaired digestion), etc. can be included as a signs and symptoms of subclinical Hypothyroidism. Also, *Dushti* of *Rasadhatu* plays a major role in pathogenesis. Many of *Rasaja Vikaras* which have been mentioned in Ayurvedic text<sup>[9]</sup> are similar to the clinical features of subclinical hypothyroidism such as *Gaurav* (heaviness), *tandra* (drowsiness/lassitude), *pandutavam* (pallor), *klabya* (impotence), *agninasha* (loss of digestive power), *sada* (exhaustion or tiredness of body), *ashradha* (disinclination of food).

So, Hypothyroidism can be considered as *anukta vikara* and discussed under *kapha dushti* and *ras dhatwagnimandya jnaya* disorder by comparing its signs and symptoms to ayurvedic terminologies.

## II. METHODOLOGY

### A. Patients

Patients fulfilling the following criteria shall be included: Diagnosed cases of subclinical hypothyroidism with TSH ranging from 5.5 uIU/ml- to 15.0 uIU/ml. Patients with clinical features of subclinical hypothyroidism, irrespective of sex, religion, profession, etc. Patients with an age limit of 19-60 years. Patients of subclinical hypothyroidism are willing to take ayurvedic medicine and sign the consent form.

Patients shall be excluded for the following criteria: Patients aged below 19 years and over 60 years. Patients suffering from congenital hypothyroidism, overt hypothyroidism, and secondary hypothyroidism. Patients with hyperthyroidism, neoplasia, toxic goitre, and who have undergone any type of thyroid surgery. Patients taking a known drug to alter thyroid hormone level (e.g., Amiodarone). Pregnant ladies and lactating mothers. Patients having any other major complicated diseases like Cardiac disease, Diabetes Mellitus, renal failure, malignant disease, thyrotoxicosis & other systemic disorders. The patient is not willing to take the trial.

This study has been approved by the Institutional Ethical Committee with no. (SKAU/Acad/2022/6746) on dated 2<sup>nd</sup> November 2022 and is conducted according to the common guidelines for clinical trials. The trial registration number is CTRI/2023/07/055295. Informed consent will be signed by all the patients.

Procurement of the drug has been done from a reliable pharmaceutical providing quality control report of the drug.

### B. Randomization

Patients will be randomly assigned to interventional and control groups in a 1:1 ratio through a computer-generated randomization sequence. A patient will only be registered once and randomized once.

### C. Study Design

In this single-blind, single-centered, randomized clinical trial all patients will be diagnosed on the basis of symptoms of hypothyroidism and TSH, T3, and T4 levels before randomization. After that Interventional group will receive *Varunadi Ghan Vati* in 500mg BD dose after the meal and the control group will receive a 1500 mg BD dose of *Kanchnar Guggulu* after the meal.




Figure 2: Study design

### D. Outcome

The primary outcome measure will be rated by assessing the clinical symptoms of hypothyroidism. Secondary outcome measures will be made using laboratory investigations like TSH, T3, T4, serum Cholesterol, Serum triglyceride, blood Urea, serum Creatinine, SGOT, SGPT, alkaline phosphate, and CBC. Outcomes will be documented at the baseline, 15<sup>th</sup>, 30<sup>th</sup>, and 45<sup>th</sup> (during treatment) and on the 75<sup>th</sup> day (post-treatment).

Table no. 1: Assessment Criteria

Sr No.	Symptom & Grading	
1	Puffiness of face & eyelids	
	Absent	0
	Occasional	1
	Daily, Periorbital oedema/puffiness in the morning only	2
	Persistent	3
2	Bilateral Peripheral Oedema -	
	No oedema	0
	Oedema on lower / upper extremities	1
	Oedema on both upper and lower extremities	2
	Oedema all over the body	3
3	Dry skin and Coarse Skin	
	No line on scrubbing with nail	0
	Faint line on scrubbing with nail	1
	Lining and even words can be written by nail	2
	Excessive <i>rukshata</i> leads to <i>kandu</i>	3
4	Breathlessness	
	Absent	0
	Occasionally, only after a strenuous workout	1
	Even on climbing upstairs, but relieved by rest	2
	Felt in routine work bathing, changing clothes	3

5	Cold intolerance	
	Absent	0
	Mild	1
	Moderate	2
	Severe	3
6	Hoarseness of Voice	
	Absent	0
	Mild	1
	Moderate	2
7	Constipation	
	Once a day	0
	Once in two days	1
	Once in three days	2
	Once in more than three days	3
8	Weakness	
	Able to exercise without difficulty	0
	Able to do mild exercise	1
	Able to do only mild work	2
	Able to do mild work with difficulty	3
	Not able to do even mild work	4
9	Fatigue	
	Normal	0
	Patient like to stand in comparison to walk	1
	Patient like to sit in comparison to stand	2
	Patient like to lie down in comparison to sitting	3
	Patient like to sleep in comparison with lying down	4
10	Body-ache	
	Normal	0
	Patient like to stand in comparison to walk	1
	Patient like to sit in comparison to stand	2
	Patient like to lie down in comparison to sitting	3
	Patient like to sleep in comparison with lying down	4
11	Menstruation:	
	Menstruation is not painful and daily activity is unaffected, 4 or more than 4 pad use/day 4-7 days duration	0
	Menstruation is painful but seldom inhibits the woman's normal activity, analgesics are not required, 3 pad use/day, 3 days duration	1
	Daily activity was affected. Analgesic drugs or therapies were needed but not as routine	2
	Activity inhibited. Poor effect of analgesic. She cannot do even her normal routine work, 1- 2 pad use/day, 1-2 days	3

12	Hair Fall	
	No Hair Fall	0
	Hair falls during combing the wet hair or after oiling the hair combing	1
	Hair falls during washing hair and normal combing	2
	Hair falls without combing	3
13	Coarse & Brittle Hair	
	Absent	0
	Mild	1
	Moderate	2
	Marked	3

### E. Interventions

Interventional Group: this group will receive *Varunadi Ghan Vati* in a dose of 500mg BD. The drug will be administered for 45 days after meals. The drug is a combination of contents as mentioned in Table no2.

Table no 2: Contents of *Varunadi Ghan Vati*

Sr No.	Sanskrit name	Botanical name	Part used	Ratio
1	<i>Varuna</i>	<i>Crateva magna</i> (Lour.) DC.	Stem bark	1 part
2	<i>Artgal</i>	<i>Xanthium strumarium</i>	Root	1part
3	<i>Shigru</i>	<i>Moringa olifera</i>	Seed	1part
4	<i>Madhushigru</i>	<i>Moringa concanensis</i>	Stem bark	1part
5	<i>Tarkari</i>	<i>Clerodendrum Phlomidis</i>	Fruit	1part
6	<i>Mesh shringi</i>	<i>Gymnema Sylvestre</i> R.Br.	Leaves	1part
7	<i>Putikaranja</i>	<i>Holoptelea integrifolia</i> Planch.	Root	1part
8	<i>Naktmal</i>	<i>Pongamia pinnata</i> (L.) Pierre	Stem bark	1part
9	<i>Morat</i>	<i>Allangium salvifolium</i>	Fruit	1part
10	<i>Agnimantha</i>	<i>Premna corymbosa</i> Rottler and Willd.	Root	1part
11	<i>Saireyaka</i>	<i>Barleria strigosa</i> Willd.	Root	1part
12	<i>Piyavasa</i>	<i>Barleria prionitis</i>	Roots	1part
13	<i>Bimbi</i>	<i>Coccinia indica</i>	Whole plant	1part
14	<i>Vasuk</i>	<i>Sesbania grandiflora</i>	Flower	1part
15	<i>Vasir</i>	<i>Achyranthes aspera</i> Retz.	Fruit	1part
16	<i>Chitraka</i>	<i>Plumbago zeylanica</i> L.	Root	1part
17	<i>Shatavari</i>	<i>Asparagus racemosus</i> Willd.	Root tuber	1part
18	<i>Bilwa</i>	<i>Aegle marmelos</i> (L.) Correa	Root	1part
19	<i>Ajshringi</i>	<i>Pistacia integerrima</i>	Leaf galls	1part
20	<i>Darbha</i>	<i>Imperata cylindrica</i>	Whole plant	1part
21	<i>Kusha</i>	<i>Desmosta chyabipinnata</i>	root	1part
22	<i>Brihati</i>	<i>Solanum anguivi</i> Lam.	Root	1part
23	<i>Nidigdhika</i>	<i>Solanum surattense</i> Burm. f.	Root	1part

Control group: This group will receive *Kanchnar guggulu* in a dose of 1500mg BD. The drug will be administered for 45 days after meals. The drug is a combination of contents as mentioned in Table no 3.

Table no 3: Contents of *Kanchnar Guggulu*

Sr No	Sanskrit name	Botanical name	Part used	Ratio
1	<i>Kanchnar</i>	<i>Bauhinia variegata</i> (L.) Benth	Bark	480gm
2	<i>Haritaki</i>	<i>Terminalia chebula</i> Retz.	Fruit	96gm
3	<i>Bibhitaki</i>	<i>Terminalia bellerica</i>	Fruits	96gm
4	<i>Amalaki</i>	<i>Emblia officinalis</i> Gaertn.	Fruits	96gm
5	<i>Sunthi</i>	<i>Zingiber officinale</i> (Rosc.)	Rhizomes	48gm
6	<i>Marica</i>	<i>Piper nigrum</i> Linn.	Seeds	48gm
7	<i>Pippali</i>	<i>Piper longum</i> Linn.	Fruits,	48gm
8	<i>Guggulu</i>	<i>Commiphora mukul</i> Hook.	Resin	996gm
9	<i>Ela</i>	<i>Elettaria cardamomum</i> (L.) malon	Seed	12gm
10	<i>Twaka</i>	<i>Cinnamomum Zeylanicum</i> Blume	Bark	12gm
11	<i>Tejpatra</i>	<i>Cinnamomum tamala</i> Nees	Leaf	12gm
12	<i>Varuna</i>	<i>Crateva magna</i> (Lour.) DC.	Stem bark	48gm

#### F. Statistics

The analysis will be as per protocol analysis. The 30 patients in each group will be studied. The information gathered on the basis of the observations was subjected to statistical analysis using SPSS and MS Excel software in terms of mean ( $\bar{x}$ ), standard deviation (S.D.) and standard error (S.E.). Unpaired t-test will be carried out at  $P < 0.05$ ,  $P < 0.01$  and  $P < 0.001$  levels. The obtained results were interpreted as:

Insignificant -  $P < 0.10$

Significant -  $P < 0.05$ ,  $< 0.01$

Highly Significant -  $P < 0.001$ .

### III. DISCUSSION

This trial compares for the first time the effectiveness of *Varunadi Ghan Vati* with *Kanchnar Guggulu* in the management of subclinical hypothyroidism. Hypothyroidism is an emerging lifestyle disorder nowadays. India has a high prevalence of Hypothyroidism, which is about 10%. It is much more common in females than in males.<sup>[5]</sup> Modern science is very well developed with advanced disease, diagnosis, and treatment techniques. Still only hormone replacement therapy for the control of endocrinal disorders such as subclinical hypothyroidism. It is lifelong therapy or no treatment given for subclinical hypothyroidism. Many studies show very little or no improvement in cognition, weight or quality of life in patients taking Levothyroxine for the milder form of subclinical hypothyroidism.<sup>[10-11]</sup> In patients with Subclinical Hypothyroidism, 2.6% each year if Thyroperoxidase (TPO) antibodies are absent and 4.3% if they are present convert into clinical hypothyroidism every year<sup>[12]</sup> Levothyroxine therapy has many side effects on the body. As Ayurveda emphasizes the treatment of preconditions (*sanchya, prakopa, prasar, purvarupa*), so that, the disease (*vyadhi utpatti*) does not progress to further stages. So, this study has been selected. According to Ayurveda, subclinical hypothyroidism can be considered as *Anukta vikara* and discussed as *Kapha dushti, dhatwagnimandya janya vhadhi*. In Hypothyroidism, the principal concern is to normalize the *Kapha dosha* and restoration of *Agni*. *Varunadi Gana* in *shushrut Samhita* is described as *Kapha doshahar*. Most of the drugs of *Varunadi Gana* are of *teekshan, ushana guna* such as *chitrak*<sup>[13]</sup> *varun*<sup>[14]</sup> are mentioned as *agnivardhak*. *Bilva*<sup>[15]</sup> is also given as *Kapha vatahar, Agni deepan*. *Kanchnar Guggulu* is a proven drug for subclinical hypothyroidism by previous research works<sup>[16]</sup>. *Dosha dushya sammurchana* causes *vyadhi utpati*. *Kanchnar guggulu* is in *gandmala rogadhikar* also given for *agnideepan* in Ayurvedic text.<sup>[17]</sup> Hence, *Varunadi Ghan Vati* and *Kanchnar Guggulu* were selected for the study. Here, an effort is undertaken to determine which remedy for subclinical hypothyroidism, *Varunadi ghan vati* or *Kanchnar Guggulu*, is more efficient. The paper outlines the methodology for a clinical trial to evaluate the effectiveness of Ayurvedic treatments for subclinical hypothyroidism. In conclusion, the paper offers valuable insights into the Ayurvedic perspective on subclinical hypothyroidism and proposes a clinical trial to investigate the efficacy of Ayurvedic treatments in managing this condition. This research has the potential to bridge the gap between traditional Ayurvedic approaches, providing treatment options for patients with subclinical hypothyroidism. However, the outcomes of the clinical trial will be essential in determining the practical applicability and effectiveness of these Ayurvedic interventions in the management of subclinical hypothyroidism.

**A. Trial Status**

This study is recruiting patients.

**B. Declaration**

- 1) *Ethics approval and consent to the participation:* This study has been approved by the institutional ethics committee with no. (SKAU/Acad/2022/6746)
- 2) *Financial Implications:* The financial allotment shall be given by Shri Krishna Ayush University for the study will be utilized and the trial will be completed within the financial limit provided by the institute.
- 3) *Followed Guidelines:* The trial is conducted according to the common guidelines of clinical trials (Declaration of Helsinki).

**REFERENCES**

- [1] Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, editors. Harrison's principles of internal medicine. 20th ed. New York: McGraw Hill Education; 2018. p. 2699.
- [2] Mujhal YP. Api text book of medicine, 9th ed. Mumbai: The Association of Physicians of India; 2015. p. 601-3.
- [3] Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH, T (4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III) J Clin Endocrinol Metabolism, 2002; 87: 489-99.
- [4] Bembien DA, Hamm RM, Morgan L, Winn P, Davis A, Barton E. Thyroid disease in the elderly. Part 2: Predictability of subclinical hypothyroidism. J Fam Pract, 1994; 38:583-8
- [5] Unnikrishnan AG, Kalra S, Sahay RK, Bantwal G, John M, Tewari Neeraj. Prevalence of hypothyroidism in adults: An epidemiological study in eight cities of India. Indian J Endocrinol Metabolism, 2013 Jul-Aug; 17(4): 647-52.
- [6] Gupt A. Astanga hridayam: vidyotini hindi commentary. reprint ed. Varanasi: Chaukhamba Bharti Academy; 2019. Sutra sthana Chapter 12, Doshbhediyaadhyaya; versus 64-6.
- [7] Shastri R, Shastri K, Chaturvedi G. Charaka samhita: elaborated vidyotini hindi commentary vyakhya. Varanasi: Chaukhamba Bharti Academy; 2019. Chikitsa sthana Chapter 15, Grahnidoshachikitsaadhyay; p. 459. 15.
- [8] Shastri R, Shastri K, Chaturvedi G. Charaka samhita: elaborated vidyotini hindi commentary vyakhya. Varanasi: Chaukhamba Bharti Academy; 2019. Sutra sthana Chapter 20, Maharogadhyay; p. 352.
- [9] Shastri R, Shastri K, Chaturvedi G. Charaka samhita elaborated vidyotini hindi commentary vyakhya. Varanasi: Chaukhamba Bharti Academy; 2019. Sutra sthana Chapter 28, Vividhshiptipitiyaadhyay; p. 502
- [10] Kong WM, Sheikh MH, Lumb PJ. A 6-month randomized trial of thyroxine treatment in women with mild subclinical hypothyroidism [published correction appears in Am J Med. 2002;113(3):264] Am J Med. 2002;112(5):348-54.
- [11] Jorde R, Waterloo K, Storhaug H, Nyren A, Sundsfjord J, Jenssen TG. Neuropsychological function and symptoms in subjects with subclinical hypothyroidism and the effect of thyroxine treatment: J Clin Endocrinol Metabolism, 2006 January; 91(1):145-53.
- [12] Vanderpump MP, Tunbridge WM, French JM. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995;43(1):55-68
- [13] Mishra SB. Bhava prakash samhita. 8thed. Varanasi: Chaukhamba Sanskrit Sansthan; 2003. Chapter 61, Kshudrarogaadhikar; p. 422.
- [14] Mishra SB, Shri. Bhava prakash samhita. 8thed. Varanasi: Chaukhamba Sanskrit Sansthan; 2003. Chapter 61, Kshudrarogaadhikar; p. 431.
- [15] Shastri SAK. Sushruta samhita. Varanasi: Chauhamba Sanskrit Sansthan; 2017. Sutra sthana Chapter 13, Jalokaavcharniyaadhyay; p. 183. xxiv
- [16] Kombe P, Kuchavar V. The evaluation of effects of kanchnar guggulu in subclinical hypothyroidism with respect to agnimadya. 2019 October- December; 10(4): 310- 60.
- [17] Murthy KR. Sharangadhara samhita. Varanasi: Vatalpana Choukhamba Publications; 1984. Chapter 7, Vatakakalpanaadhyay; verse 95-8.



10.22214/IJRASET



45.98



IMPACT FACTOR:  
7.129



IMPACT FACTOR:  
7.429



# INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Call : 08813907089  (24\*7 Support on Whatsapp)